Exploration of Cardiology

From: A case report of successful management of peripartum cardiomyopathy

Table 1. Complete blood chemistry and hematological profile results on admission

Test	Results/Units	Reference range
Complete blood count
White blood cells	7.1 × 10⁹/L	3.5–9.5 × 10⁹/L
Hemoglobin	164 g/L	115–150 g/L
Hematocrit	49.0%	35.0–45.0%
Platelets	262 × 10⁹/L	94–268 × 10⁹/L
Neutrophils	4.53 × 10⁹/L	1.8–6.3 × 10⁹/L
C-reactive protein	< 0.50 mg/L	0–8 mg/L
Coagulation profile
Prothrombin time	12.3 s	9.4–13.8 s
International normalized ratio	1.08	0.76–1.16
Activated partial thromboplastin time	26.6 s	24–40 s
D-dimers	336.69 μg/L	0–232 μg/L
Urea and electrolytes
Sodium	141.7 mmol/L	137.0–147.0 mmol/L
Potassium	4.66 mmol/L	3.50–5.30 mmol/L
Urea nitrogen	6.88 mmol/L	2.6–7.5 mmol/L
Creatinine	68.4 μmol/L	41.0–73.0 μmol/L
eGFR	111.84 mL/min/1.73 m²	> 90 mL/min/1.73 m²
Liver function tests
Alanine aminotransferase	385.8 U/L	7.0–40.0 U/L
Aspartate transaminase	169.8 U/L	13.0–35.0 U/L
Albumin	35.4 g/L	40.0–55.0 g/L
Globulin	21.5 g/L	20.0–40.0 g/L
Total protein	56.9 g/L	65.0–85.0 g/L
NTproBNP	10,198 pg/mL	0–450 pg/mL

Return to article view

NTproBNP: N-terminal pro-B-type natriuretic peptide

Declarations

Author contributions

JG: Conceptualization, Writing—original draft, Writing—review & editing. XW: Conceptualization, Writing—original draft, Writing—review & editing, Supervision. Both authors read and approved the submitted version.

Conflicts of interest

The authors declare that they have no conflicts of interest.

Ethical approval

The study complies with the Declaration of Helsinki (2024 version). As it was routine treatment, ethical approval was not required for this study, according to the local committee.

Consent to participate

Informed consent to participate in the study was obtained from all participants.

Consent to publication

Informed consent to publication was obtained from the relevant participant.

Availability of data and materials

The raw data supporting the conclusions of this manuscript will be made available by the authors, without undue reservation, to any qualified researcher.

Funding

Not applicable.

Copyright

Publisher’s note

Open Exploration maintains a neutral stance on jurisdictional claims in published institutional affiliations and maps. All opinions expressed in this article are the personal views of the author(s) and do not represent the stance of the editorial team or the publisher.

References

Asad ZUA, Maiwand M, Farah F, Dasari TW. Peripartum cardiomyopathy: A systematic review of the literature. Clin Cardiol. 2018;41:693–7. [DOI] [PubMed] [PMC]

Davis MB, Arany Z, McNamara DM, Goland S, Elkayam U. Peripartum Cardiomyopathy: JACC State-of-the-Art Review. J Am Coll Cardiol. 2020;75:207–21. [DOI] [PubMed]

Safira A, Tjahjadi AK, Adytia GJ, Waitupu A, Sutanto H. Peripartum cardiomyopathy unveiled: Etiology, diagnosis, and therapeutic insights. Curr Probl Cardiol. 2024;49:102474. [DOI] [PubMed]

Sliwa K, Hilfiker-Kleiner D, Petrie MC, Mebazaa A, Pieske B, Buchmann E, et al.; Heart Failure Association of the European Society of Cardiology Working Group on Peripartum Cardiomyopathy. Current state of knowledge on aetiology, diagnosis, management, and therapy of peripartum cardiomyopathy: a position statement from the Heart Failure Association of the European Society of Cardiology Working Group on peripartum cardiomyopathy. Eur J Heart Fail. 2010;12:767–78. [DOI] [PubMed]

Ballo P, Betti I, Mangialavori G, Chiodi L, Rapisardi G, Zuppiroli A. Peripartum cardiomyopathy presenting with predominant left ventricular diastolic dysfunction: efficacy of bromocriptine. Case Rep Med. 2012;2012:476903. [DOI] [PubMed] [PMC]

Pearson GD, Veille JC, Rahimtoola S, Hsia J, Oakley CM, Hosenpud JD, et al. Peripartum cardiomyopathy: National Heart, Lung, and Blood Institute and Office of Rare Diseases (National Institutes of Health) workshop recommendations and review. JAMA. 2000;283:1183–8. [DOI] [PubMed]

Mehta NJ, Mehta RN, Khan IA. Peripartum cardiomyopathy: clinical and therapeutic aspects. Angiology. 2001;52:759–62. [DOI] [PubMed]

DeFilippis EM, Haythe JH, Walsh MN, Kittleson MM. Intersection of Heart Failure and Pregnancy: Beyond Peripartum Cardiomyopathy. Circ Heart Fail. 2021;14:e008223. [DOI] [PubMed]

Hilfiker-Kleiner D, Haghikia A, Nonhoff J, Bauersachs J. Peripartum cardiomyopathy: current management and future perspectives. Eur Heart J. 2015;36:1090–7. [DOI] [PubMed] [PMC]

10.

Bauersachs J, König T, van der Meer P, Petrie MC, Hilfiker-Kleiner D, Mbakwem A, et al. Pathophysiology, diagnosis and management of peripartum cardiomyopathy: a position statement from the Heart Failure Association of the European Society of Cardiology Study Group on peripartum cardiomyopathy. Eur J Heart Fail. 2019;21:827–43. [DOI] [PubMed]

11.

Hilfiker-Kleiner D, Kaminski K, Podewski E, Bonda T, Schaefer A, Sliwa K, et al. A cathepsin D-cleaved 16 kDa form of prolactin mediates postpartum cardiomyopathy. Cell. 2007;128:589–600. [DOI] [PubMed]

12.

Sliwa K, Mebazaa A, Hilfiker-Kleiner D, Petrie MC, Maggioni AP, Laroche C, et al. Clinical characteristics of patients from the worldwide registry on peripartum cardiomyopathy (PPCM): EURObservational Research Programme in conjunction with the Heart Failure Association of the European Society of Cardiology Study Group on PPCM. Eur J Heart Fail. 2017;19:1131–41. [DOI] [PubMed]

13.

Regitz-Zagrosek V, Roos-Hesselink JW, Bauersachs J, Blomström-Lundqvist C, Cífková R, De Bonis M, et al.; ESC Scientific Document Group. 2018 ESC Guidelines for the management of cardiovascular diseases during pregnancy. Eur Heart J. 2018;39:3165–241. [DOI] [PubMed]

14.

Sliwa K, Skudicky D, Bergemann A, Candy G, Puren A, Sareli P. Peripartum cardiomyopathy: analysis of clinical outcome, left ventricular function, plasma levels of cytokines and Fas/APO-1. J Am Coll Cardiol. 2000;35:701–5. [DOI] [PubMed]

15.

McNamara DM, Elkayam U, Alharethi R, Damp J, Hsich E, Ewald G, et al.; IPAC Investigators. Clinical Outcomes for Peripartum Cardiomyopathy in North America: Results of the IPAC Study (Investigations of Pregnancy-Associated Cardiomyopathy). J Am Coll Cardiol. 2015;66:905–14. [DOI] [PubMed] [PMC]